Last updated: February 17, 2026
Product Overview
NDC 16729-0542 represents Ozempic (semaglutide) injection, 1 mg. It is indicated for adults with type 2 diabetes mellitus to improve glycemic control. The drug belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class and also has approved uses for weight management under certain conditions.
Market Dynamics
1. Market Size and Growth
- The global GLP-1 receptor agonist market was valued at approximately $16.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 11.5% through 2030 [1].
- The U.S. market for injectable diabetes medications accounts for roughly 65% of the global market, driven by high prevalence rates and reimbursement accessibility [2].
- The U.S. Department of Health and Human Services reports over 37 million Americans with diabetes, with type 2 constituting 90-95% of cases [3].
2. Competitive Landscape
Key competitors include:
| Drug Name |
Manufacturer |
Indication |
Price Range (Monthly) |
| Trulicity (dulaglutide) |
Eli Lilly |
Diabetes, weight loss |
$800–$950 |
| Victoza (liraglutide) |
Novo Nordisk |
Diabetes, weight loss |
$850–$900 |
| Wegovy (semaglutide) |
Novo Nordisk |
Weight management |
$1,350/month |
3. Market Share Data
- Ozempic held approximately 38% of the GLP-1 market in 2022 [4].
- The drug's indication expansion to weight management has increased prescriptions, especially among obese non-diabetics.
Pricing Trends
1. Current Price Points
- Wholesale acquisition cost (WAC) for NDC 16729-0542 is approximately $890 per month.
- Insurance reimbursements often reduce patient out-of-pocket costs to roughly $20–$50 for commercially insured patients.
2. Price Drivers
- Patent exclusivity until 2030 limits generic competition.
- Label expansion for weight management increases demand.
- Entry of biosimilars is unlikely before patent expiration.
3. Reimbursement Factors
- CMS (Centers for Medicare & Medicaid Services) adjusts reimbursements annually.
- Cost-sharing impacts patient utilization rates.
Regulatory and Patent Considerations
- The drug's primary patent protection extends through 2030, with potential data exclusivity until 2033 [5].
- No biosimilar approvals are expected before patent expiration, supporting current pricing levels.
Forecasting Market and Price Dynamics
| Year |
Estimated Market Size (USD Billion) |
Average Monthly Price |
Key Factors |
| 2023 |
$18.0 |
$890 |
Continued demand for diabetes and weight management |
| 2025 |
$22.4 |
$870–$900 |
Increased acceptance, expanded indications, no biosimilars |
| 2030 |
$30.0 |
Stabilizes around $850 |
Patent exclusivity, competition limited, steady demand |
Price Projections: Monthly price likely remains stable through 2025. Minimal declines expected before 2030 due to patent protections. Post-2030, biosimilar entry could reduce prices by 20–40%.
Key Challenges and Risks
- Competition from biosimilars post-2030.
- Price sensitivity among payers and patients.
- Regulatory changes affecting coverage and reimbursement.
- Potential emergence of new therapies with better efficacy or safety profiles.
Key Takeaways
- NDC 16729-0542 (Ozempic 1 mg) commands approximately $890/month in the U.S.
- The drug dominates the GLP-1 market, with demand driven by diabetes and weight management indications.
- Market growth is projected at a CAGR of over 11.5% through 2030, reaching an estimated $30 billion.
- Patent protections till 2030 limit biosimilar competition, sustaining high pricing.
- Post-2030, biosimilar entry could reduce prices by up to 40%, impacting revenue streams.
Frequently Asked Questions
1. How does Ozempic's pricing compare to similar GLP-1 receptor agonists?
Ozempic’s monthly price (~$890) aligns with or slightly exceeds Trulicity and Victoza, reflecting its market share and label expansion. Wegovy’s higher dosage and indication for weight management contribute to a higher price point.
2. What factors could lead to price declines before 2030?
Patent expiry, biosimilar development, and payer negotiations could lower prices by 20–40%. Expanded use for weight loss may also influence pricing strategies.
3. How does insurance coverage impact patient costs?
Reimbursement reduces patient out-of-pocket expenses to as low as $20–$50 monthly under commercial plans, affecting demand and adherence.
4. What is the outlook for biosimilar competition?
Biosimilar versions are unlikely before 2030 due to patent protections. Post-expiry, biosimilar market entry may force price reductions.
5. What potential developments can influence the market?
New formulations, combination products, and enhanced indications could sustain or grow market share, while regulatory or patent issues may hinder competition.
Citations
[1] MarketsandMarkets, "GLP-1 Receptor Agonists Market by Product," 2022.
[2] IQVIA, "US Market for Diabetes Medications," 2022.
[3] CDC, "National Diabetes Statistics Report," 2020.
[4] Evaluate Pharma, "GLP-1 Market Share," 2022.
[5] FDA, "Patent Status and Exclusivity Data," 2022.
